Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.

Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL.

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1696-705. doi: 10.1161/ATVBAHA.113.301373. Epub 2013 Mar 21.

2.

Importance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis.

Weibel GL, Drazul-Schrader D, Shivers DK, Wade AN, Rothblat GH, Reilly MP, de la Llera-Moya M.

Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):17-25. doi: 10.1161/ATVBAHA.113.302437. Epub 2013 Nov 7.

3.

Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.

van den Berg MJ, van der Graaf Y, de Borst GJ, Kappelle LJ, Nathoe HM, Visseren FL; SMART Study Group.

Am J Cardiol. 2016 Sep 15;118(6):804-10. doi: 10.1016/j.amjcard.2016.06.048. Epub 2016 Jun 28.

4.

Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk.

Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J, Kathiresan S; CARDIoGRAM Consortium, Roberts R, McPherson R, Allayee H, Hazen SL.

Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2803-12. doi: 10.1161/ATVBAHA.112.253930. Epub 2012 Sep 13.

5.

High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease.

Ishikawa T, Ayaori M, Uto-Kondo H, Nakajima T, Mutoh M, Ikewaki K.

Atherosclerosis. 2015 Sep;242(1):318-22. doi: 10.1016/j.atherosclerosis.2015.06.028. Epub 2015 Jul 13.

PMID:
26246268
6.

Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.

Kappelle PJ, Gansevoort RT, Hillege HJ, Wolffenbuttel BH, Dullaart RP; PREVEND Study Group.

J Clin Lipidol. 2013 Jan-Feb;7(1):56-64. doi: 10.1016/j.jacl.2012.05.003. Epub 2012 May 22.

PMID:
23351584
7.

The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.

de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH.

Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158. Epub 2010 Jan 14.

8.

Usefulness of cardiac biomarker score for risk stratification in stable patients undergoing elective cardiac evaluation across glycemic status.

Tang WH, Iqbal N, Wu Y, Hazen SL.

Am J Cardiol. 2013 Feb 15;111(4):465-70. doi: 10.1016/j.amjcard.2012.10.027. Epub 2012 Dec 4.

9.

Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.

Nakamura T, Obata JE, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, Watanabe K, Watanabe Y, Mishina H, Kugiyama K.

Atherosclerosis. 2011 Sep;218(1):163-7. doi: 10.1016/j.atherosclerosis.2011.04.040. Epub 2011 May 6.

PMID:
21605862
10.

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.

van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ.

J Am Coll Cardiol. 2008 Feb 12;51(6):634-42. doi: 10.1016/j.jacc.2007.09.060.

11.
12.

Clinical and genetic association of serum ceruloplasmin with cardiovascular risk.

Tang WH, Wu Y, Hartiala J, Fan Y, Stewart AF, Roberts R, McPherson R, Fox PL, Allayee H, Hazen SL.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):516-22. doi: 10.1161/ATVBAHA.111.237040. Epub 2011 Nov 10.

13.

High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.

Kempen HJ, Asztalos BF, Moerland M, Jeyarajah E, Otvos J, Kallend DG, Bellibas SE, Wijngaard PL.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):736-42. doi: 10.1161/ATVBAHA.115.307052. Epub 2016 Feb 25.

14.
15.

HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity.

Borja MS, Ng KF, Irwin A, Hong J, Wu X, Isquith D, Zhao XQ, Prazen B, Gildengorin V, Oda MN, Vaisar T.

J Lipid Res. 2015 Oct;56(10):2002-9. doi: 10.1194/jlr.M059865. Epub 2015 Aug 7.

16.

Plasma ceruloplasmin, a regulator of nitric oxide activity, and incident cardiovascular risk in patients with CKD.

Kennedy DJ, Fan Y, Wu Y, Pepoy M, Hazen SL, Tang WH.

Clin J Am Soc Nephrol. 2014 Mar;9(3):462-7. doi: 10.2215/CJN.07720713. Epub 2013 Dec 5.

17.

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.

18.

HDL cholesterol efflux capacity and incident cardiovascular events.

Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW.

N Engl J Med. 2014 Dec 18;371(25):2383-93. doi: 10.1056/NEJMoa1409065. Epub 2014 Nov 18.

19.

Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease.

Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, Plebani M, Rossi GP.

Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):725-32. doi: 10.1161/ATVBAHA.114.304964. Epub 2015 Jan 22.

20.

Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study.

Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A.

Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):661-70. Epub 2006 Dec 14.

Supplemental Content

Support Center